KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to $1.4 billion.

  • Edwards Lifesciences' Accumulated Expenses fell 2013.41% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 2013.41%. This contributed to the annual value of $1.3 billion for FY2024, which is 4974.31% up from last year.
  • Edwards Lifesciences' Accumulated Expenses amounted to $1.4 billion in Q3 2025, which was down 2013.41% from $1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Edwards Lifesciences' Accumulated Expenses peaked at $1.7 billion during Q3 2024, and registered a low of $739.5 million during Q3 2022.
  • Moreover, its 5-year median value for Accumulated Expenses was $876.1 million (2023), whereas its average is $999.7 million.
  • Per our database at Business Quant, Edwards Lifesciences' Accumulated Expenses soared by 7043.95% in 2024 and then crashed by 2013.41% in 2025.
  • Over the past 5 years, Edwards Lifesciences' Accumulated Expenses (Quarter) stood at $802.3 million in 2021, then dropped by 0.91% to $795.0 million in 2022, then grew by 7.72% to $856.4 million in 2023, then surged by 49.74% to $1.3 billion in 2024, then rose by 8.69% to $1.4 billion in 2025.
  • Its Accumulated Expenses stands at $1.4 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.2 billion for Q1 2025.